GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Net-Net Working Capital

Renovacor (Renovacor) Net-Net Working Capital : $2.31 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Renovacor Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Renovacor's Net-Net Working Capital for the quarter that ended in Sep. 2022 was $2.31.

The industry rank for Renovacor's Net-Net Working Capital or its related term are showing as below:

RCOR's Price-to-Net-Net-Working-Capital is not ranked
in the Biotechnology industry.
Industry Median: 4.22 vs RCOR: 1.39

Renovacor Net-Net Working Capital Historical Data

The historical data trend for Renovacor's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Net-Net Working Capital Chart

Renovacor Annual Data
Trend Dec20 Dec21
Net-Net Working Capital
0.31 3.06

Renovacor Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only 2.94 3.06 3.50 3.26 2.31

Competitive Comparison of Renovacor's Net-Net Working Capital

For the Biotechnology subindustry, Renovacor's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovacor's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovacor's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Renovacor's Price-to-Net-Net-Working-Capital falls into.



Renovacor Net-Net Working Capital Calculation

Renovacor's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2021 is calculated as

Net-Net Working Capital(A: Dec. 2021 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(78.79+0.75 * 0+0.5 * 0-27.455
-0-0)/16.756
=3.06

Renovacor's Net-Net Working Capital (NNWC) per share for the quarter that ended in Sep. 2022 is calculated as

Net-Net Working Capital(Q: Sep. 2022 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(53.713+0.75 * 0+0.5 * 0-15.034
-0-0)/16.7694
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Renovacor  (AMEX:RCOR) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Renovacor Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Renovacor's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovacor (Renovacor) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 8142, Greenwich, CT, USA, 06836
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Executives
Joseph S Carroll officer: Chief Accounting Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino director C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr. director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll officer: Chief Financial Officer
Jonas Grossman director 17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook director, officer: Chief Executive Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen officer: Chief Scientific Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran officer: Chief Medical Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco officer: Interim CFO

Renovacor (Renovacor) Headlines